These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25904915)

  • 1. Immunogenicity of Anti-TNF-α Biotherapies: I. Individualized Medicine Based on Immunopharmacological Evidence.
    Bendtzen K
    Front Immunol; 2015; 6():152. PubMed ID: 25904915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists.
    Bendtzen K
    Discov Med; 2013 Apr; 15(83):201-11. PubMed ID: 23636137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of Anti-TNF-α Biotherapies: II. Clinical Relevance of Methods Used for Anti-Drug Antibody Detection.
    Bendtzen K
    Front Immunol; 2015; 6():109. PubMed ID: 25904911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine.
    Bendtzen K
    Immunotherapy; 2012 Nov; 4(11):1167-79. PubMed ID: 23194366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics in IBD: ready for prime time?
    Roblin X; Rinaudo M; Sparrow MP; Moreau A; Phelip JM; Genin C; Lamarque D; Paul S
    Curr Drug Targets; 2014; 15(11):1049-55. PubMed ID: 25173707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.
    Bendtzen K; Ainsworth M; Steenholdt C; Thomsen OØ; Brynskov J
    Scand J Gastroenterol; 2009; 44(7):774-81. PubMed ID: 19140087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].
    Steenholdt C; Ainsworth M; Thomsen OØ; Brynskov J; Bendtzen K
    Ugeskr Laeger; 2010 Jan; 172(1):44-7. PubMed ID: 20056095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized therapy with TNF-inhibitors in Crohn's disease: optimizing treatment outcomes by monitoring drug levels and anti-drug antibodies.
    Steenholdt C
    Dan Med J; 2016 Aug; 63(8):. PubMed ID: 27477799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.
    van Schie KA; Wolbink GJ; Rispens T
    MAbs; 2015; 7(4):662-71. PubMed ID: 25962087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis.
    Arends S; Lebbink HR; Spoorenberg A; Bungener LB; Roozendaal C; van der Veer E; Houtman PM; Griep EN; Limburg PC; Kallenberg CG; Wolbink GJ; Brouwer E
    Clin Exp Rheumatol; 2010; 28(5):661-8. PubMed ID: 20822711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies.
    Svenson M; Geborek P; Saxne T; Bendtzen K
    Rheumatology (Oxford); 2007 Dec; 46(12):1828-34. PubMed ID: 18032541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study.
    Spadaro A; Lubrano E; Marchesoni A; D'Angelo S; Ramonda R; Addimanda O; Perrotta FM; Olivieri I; Punzi L; Salvarani C
    Rheumatology (Oxford); 2013 Oct; 52(10):1914-9. PubMed ID: 23878312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of anti-tumour necrosis factor drugs in rheumatic diseases.
    Spinelli FR; Valesini G
    Clin Exp Rheumatol; 2013; 31(6):954-63. PubMed ID: 23981925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis.
    Zisapel M; Zisman D; Madar-Balakirski N; Arad U; Padova H; Matz H; Maman-Sarvagyl H; Kaufman I; Paran D; Feld J; Litinsky I; Wigler I; Caspi D; Elkayam O
    J Rheumatol; 2015 Jan; 42(1):73-8. PubMed ID: 25399390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study.
    Spadaro A; Punzi L; Marchesoni A; Lubrano E; Mathieu A; Cantini F; Olivieri I; Salvarani C; Scarpa R; Scrivo R; Ramonda R; Porru G; D'Angelo S; Catanoso M; Atteno M; Valesini G
    Rheumatology (Oxford); 2010 Jun; 49(6):1107-11. PubMed ID: 20223813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease.
    Ha C; Mathur J; Kornbluth A
    Expert Rev Gastroenterol Hepatol; 2015 Apr; 9(4):497-505. PubMed ID: 25600263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations in the Immunogenicity Assessment Strategy for Oligonucleotide Therapeutics (ONTs).
    Bano N; Ehlinger C; Yang TY; Swanson M; Allen S
    AAPS J; 2022 Aug; 24(5):93. PubMed ID: 36028587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
    Cozzani E; Burlando M; Parodi A
    G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assays and strategies for immunogenicity assessment of biological agents.
    Nencini F; Pratesi S; Petroni G; Matucci A; Maggi E; Vultaggio A
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S4-6. PubMed ID: 25381974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.